Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD4 T cells in tumor immunity.

Mara Gerloni1, Maurizio Zanetti

  • 1The Laboratory of Immunology, Department of Medicine and Cancer Center, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0837, USA. mgerloni@ucsd.edu

Springer Seminars in Immunopathology
|June 21, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Triple-negative breast cancer, pregnancy, and HLA alloreactivity: a cause for concern?

Frontiers in oncology·2026
Same author

NeoPrecis: enhancing immunotherapy response prediction through integration of qualified immunogenicity and clonality-aware neoantigen landscapes.

Nature communications·2026
Same author

Correction: Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern.

PLoS pathogens·2025
Same author

NeoPrecis: Enhancing Immunotherapy Response Prediction through Integration of Qualified Immunogenicity and Clonality-Aware Neoantigen Landscapes.

bioRxiv : the preprint server for biology·2025
Same author

Evaluation of SOX4 levels in multiple myeloma patients.

Haematologica·2025
Same author

A rifamycin SV in situ gelling formulation for the treatment of pouchitis.

Drug delivery and translational research·2025

CD4 T cells are crucial for anti-tumor immunity, complementing CD8 T cells. Understanding their role in tumor antigen recognition and regulation is key for developing effective cancer vaccines.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • T cell immunity, particularly CD8 T lymphocytes restricted by MHC class I, is vital for anti-tumor responses.
  • Emerging evidence highlights a significant role for CD4 T cells, restricted by MHC class II, in protective anti-tumor immunity.

Purpose of the Study:

  • To discuss the multifaceted role of MHC class II-restricted T cells in anti-tumor responses and regulation.
  • To explore CD4 T cell immunity in tumor protection, antigen recognition, synergistic effects, and regulatory impacts.

Main Methods:

  • Review of existing literature and research findings on CD4 T cell functions in cancer immunity.
  • Analysis of animal models and human studies concerning tumor antigens and T cell responses.

Related Experiment Videos

Main Results:

  • CD4 T cells contribute significantly to anti-tumor protection through various mechanisms.
  • Specific tumor antigens recognized by human CD4 T cells have been identified.
  • Cooperation between distinct CD4 T cells can enhance responses to weak tumor antigens.
  • Regulatory CD4 T cells can negatively impact anti-tumor T cell activity.

Conclusions:

  • A comprehensive understanding of CD4 T cell roles is essential for advancing cancer immunotherapy.
  • This knowledge can inform the design of improved therapeutic cancer vaccines targeting T cell responses.